Annexon, Inc. ANNX

ANNX Company Overview

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune, neuroinflammatory, and neurodegenerative diseases through targeted inhibition of the classical complement pathway. The company operates within the biotechnology and immunology sectors, with its core strategy centered on modulating complement-mediated inflammation while preserving broader immune system function. Annexon’s primary revenue source has historically consisted of collaboration and licensing arrangements, while its long-term commercial strategy depends on successful clinical development and regulatory approval of its therapeutic candidates.

The company’s lead programs are designed around inhibition of the complement protein C1q, which Annexon believes plays a central role in inflammatory damage associated with multiple serious diseases. Key therapeutic candidates have included ANX005, ANX007, and other complement-targeting biologics intended for neurological and ophthalmic indications. Annexon was founded in 2011 and became publicly traded through an initial public offering in 2020. Its development strategy has evolved from broad complement biology research into a more concentrated focus on late-stage rare disease and neuroinflammatory indications with high unmet medical need.